Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

unknown240%
completed240%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

NCT04664972
terminatedphase_3

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

NCT00617656
completedphase_2

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

NCT00173888
unknownphase_2

Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

NCT01312311
unknownphase_2

Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer

NCT00980603

Clinical Trials (5)

Showing 5 of 5 trials
NCT04664972Phase 2

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Completed
NCT00617656Phase 3

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

Terminated
NCT00173888Phase 2

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT01312311Phase 2

Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Unknown
NCT00980603Phase 2

Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5